Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
:GH
GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.14 - $53.42
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.21M
Market Cap
$5.76B
Enterprise Value$7.16B
Total Cash (Recent Filing)$629.14M
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Oct 30, 2025EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding124,705,860
10 Day Avg. Volume3,027,649
30 Day Avg. Volume2,214,167
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue8.64
Enterprise Value/Gross Profit13.75
Enterprise Value/Ebitda-17.34
Forecast
1Y Price Target
$61.86Price Target Upside33.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Product Launch And Portfolio ExpansionGH is benefiting from the launch of multiple products including its Shield CRC screening blood-based assay, Reveal MRD and G360 Tissue—driving 31% growth in the quarter.
Regulatory And Market RecognitionShield MCED received a Breakthrough Device designation from the FDA, highlighting its potential impact in the diagnostics market.
Bears Say
Competitive PressureUpcoming blood-based colorectal cancer screening data from a competitor may cause a near-term overhang for Guardant Health shares.
Investor Concerns And DelaysThe perceived delay and no formal timeline for V2 data unveiling is likely to impact investor positioning, especially in the near term.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $20.14 and its highest was $53.42 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $5.76B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Oct 30, 2025 which is in 83 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Jul 30, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.741 by -$0.059.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.8.
How many shares outstanding does Guardant Health have?
Guardant Health has 124,705,860 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.741. Following the earnings report the stock price went down -9.316%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.86 (33.98% Upside)
$61.86 (33.98% Upside)
Blogger Sentiment
Bullish
GH Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $972.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.65%
12-Months-Change
Fundamentals
Return on Equity
-4584.47%
Trailing 12-Months
Asset Growth
-17.23%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
GH Company Deck
GH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance across all major business segments, with significant revenue growth and improved gross margins. While there are minor concerns about ASP adjustments and regulatory uncertainties, the overall outlook remains positive due to strong execution and increased guidance.View all GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$61.86
▲(33.98% Upside)
Technical Analysis
Ownership Overview
3.87% Insiders
28.38% Mutual Funds
0.31% Other Institutional Investors
49.57% Public Companies and Individual Investors